[Skip to Navigation]
Sign In
Clinicopathologic Reports, Case Reports, and Small Case Series
August 2007

Corneal Perforation After Conductive Keratoplasty in a Patient With Previously Undiagnosed Sjögren Syndrome

Arch Ophthalmol. 2007;125(8):1131-1132. doi:10.1001/archopht.125.8.1131

Conductive keratoplasty (CK) was approved by the US Food and Drug Administration in March 2004 for the correction of hyperopia ranging from +0.75 to +3.00 diopters (D) and 0.75 D or less of cylinder in patients older than 40 years.1 With CK, hyperopic correction is achieved through the use of a nonablative radiofrequency that shrinks corneal stromal collagen and steepens the central cornea. A keratoplast is used to apply 8 to 32 treatment spots at the 6-, 7-, or 8-mm optical zone.

Patients chosen for CK are carefully screened to avert ocular complications. We report the case of a patient with previously undiagnosed Sjögren syndrome who developed corneal perforation after CK.

Report of a Case

A 52-year-old Chinese woman with uncorrected visual acuity of 20/25 OU and dry eyes with normal meibomian gland status underwent uncomplicated CK of the right eye because of hyperopia (16 spots at 7- and 8-mm optical zones) for planned monovision on March 14, 2005, in Hong Kong. One week later, her manifest refraction was −0.25 + 0.25 × 90, uncorrected vision was 20/20−2, and near vision was Jaeger 3. Postoperative inferior corneal punctate staining was treated with artificial tears.

On March 31, 2005, 2 areas of full-thickness corneal perforation at the nasal and temporal CK-treated spots with iris plugging had developed. Treatment with oral acetazolamide and ascorbic acid, as well as 1% atropine sulfate, was given and the eye was patched. On April 4, 2005, the patient was taken to the operating room and the temporal iris plug was freed; the nasal iris plug was not removed to enable vascularization of the cornea. Glue was applied and a bandage contact lens placed. Serologic testing results revealed that the patient was positive for antinuclear antibody (1:320; positive, >160) and had antibodies to SS-A and SS-B (immune status ratio, 4.6 and 4.7, respectively; positive, >1.2). The diagnosis of Sjögren syndrome was made; the patient was treated systemically with celecoxib and prednisone.

The patient came to the Stanford University Eye Center, Stanford, California, for consultation on June 24, 2005. On examination, her visual acuity was counting fingers OD and 20/20 OS. Slitlamp examination revealed a large plug of glue over the right central cornea with an overlying bandage contact lens. The infranasal cornea appeared thinned and vascularized at the area of previous perforation. Sixteen CK spots were seen. Penetrating keratoplasty was recommended (Figure).

Corneal perforation after conductive keratoplasty in a patient with previously undiagnosed Sjögren syndrome. Note conductive keratoplasty spots on the superior cornea and glue over the area of the corneal perforation.

Corneal perforation after conductive keratoplasty in a patient with previously undiagnosed Sjögren syndrome. Note conductive keratoplasty spots on the superior cornea and glue over the area of the corneal perforation.


To our knowledge, this is the first reported case of corneal perforation in a patient who underwent CK having undiagnosed Sjögren syndrome. Sjögren syndrome, a chronic autoimmune inflammatory disease of the exocrine glands, including the lacrimal gland, predisposes to cornea stromal degradation and thinning, ulceration, and perforation as a result of diminished tear secretion, corneal epithelial breakdown, and enzymatic degradation of collagen by inflammatory cells.2 Corneal stromal degradation and thinning can be the initial sign of primary Sjögren syndrome.3

In patients with chronic dry eye before CK, it is important to evaluate for Sjögren syndrome. Correct diagnosis before refractive surgery may identify patients who may not be appropriate candidates for CK and prevent unnecessary postoperative complications.

Correspondence: Dr Manche, Department of Ophthalmology, Stanford University School of Medicine, 900 Blake Wilbur Dr, Stanford, CA 94305 (Edward.manche@stanford.edu).

Financial Disclosure: None reported.

McDonald  MBHersh  PSManche  EE  et al.  Conductive keratoplasty for the correction of low to moderate hyperopia: US clinical trial 1-year results on 355 eyes.  Ophthalmology 2002;109 (11) 1978- 1990PubMedGoogle ScholarCrossref
Fox  RI Sjögren's syndrome.  Lancet 2005;366 (9482) 321- 331PubMedGoogle ScholarCrossref
Vivino  FBMinerva  PHuang  CH  et al.  Corneal melt as the initial presentation of primary Sjögren's syndrome.  J Rheumatol 2001;28 (2) 379- 382PubMedGoogle Scholar